Ivonescimab Shows Significant Survival Advantage Over Pembrolizumab in Advanced Lung Cancer

A new immunotherapy drug called ivonescimab has demonstrated significantly improved overall survival compared to pembrolizumab as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) that is PD-L1 positive, according to interim results from the phase 3 HARMONi-2 trial presented at the 2026 IASLC World Conference on Lung Cancer. This breakthrough finding represents an important advancement in treating one of the most common and aggressive forms of lung cancer. The results suggest that ivonescimab may offer patients with this difficult-to-treat condition a better chance of improved outcomes and extended survival times. These findings could lead to changes in how advanced lung cancer is treated globally, potentially offering hope to thousands of patients seeking more effective treatment options.